FDA Quality Metrics Program Could Reshape Inspection Scheduling

FDA is advancing its Quality Metrics Reporting Program with the potential to fundamentally alter how frequently manufacturing establishments face routine surveillance inspections. For plant heads and QA directors operating under 21 CFR Part 211, the program signals a shift toward quantitative, data-driven quality surveillance, where facilities that demonstrate sustainable compliance through metrics may see reduced inspection frequency and duration. The agency intends to analyze submitted quality metrics data to obtain objective measures of manufacturing quality and reliability, integrating results into its comprehensive quality surveillance program.

The program builds on nearly two decades of regulatory evolution. FDA first outlined its intent to implement a modern, risk-based pharmaceutical quality assessment system in its 2004 report, "Pharmaceutical CGMPs for the 21st Century." The 2012 Food and Drug Administration Safety and Innovation Act granted the agency authority to collect pharmaceutical manufacturing records from regulated industry as part of risk-based oversight. A 2013 Federal Register notice (78 FR 9928) sought public input on using quality metrics data to evaluate manufacturing quality and understand underlying causes of product shortages. A 2014 Brookings Institute workshop further shaped the approach by convening manufacturers, purchasers, regulators, and other stakeholders.

At its core, the program treats quality metrics as objective tools to measure, evaluate, and monitor the product and process lifecycle. FDA has stated that CGMP compliance alone does not indicate whether a manufacturer is investing in improvements or striving for sustainable compliance, defined as consistent control over manufacturing performance and quality. The agency views effective use of quality metrics as one characteristic of robust site Quality Management Maturity (QMM), and as a contributor to an effective Pharmaceutical Quality System (PQS) aligned with continual improvement principles familiar to those working within ICH Q10 frameworks.

For operations and supply chain leaders, the implications extend beyond inspection readiness. FDA has indicated that quality metrics data could improve prediction and possibly mitigation of future drug shortages, while also assisting in identifying products at risk for quality-related recalls. Quality metrics also play a role in supplier selection and can inform oversight of contract activities and material suppliers, helping determine appropriate monitoring activities to minimize supply chain disruptions. Facilities that proactively build metrics into their PQS stand to demonstrate sustainable compliance posture ahead of anticipated program implementation.

The FDA published its updated quality metrics resource on April 19, 2026. Full details are available on the FDA Quality Metrics for Drug Manufacturing page.